If you have been reading about CAS Registry Number and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
== External links == CD49b+antigen at the U.S. National Library of Medicine Medical Subject Headings (MeSH) PDBe-KB provides an overview of all the structure information available in the PDB for Human Integrin alpha 2 "ITGA2". Cell Migration Gateway.{{cite web}}: CS1 maint: deprecated archival service (link) Human ITGA2 genome location and ITGA2 gene details page in the UCSC Genome Browser.
The discovery posed a problem, since sales of enalapril were strong for Merck, and the company did not want to diminish those sales. Merck ended up entering into an agreement with Zeneca under which Zeneca received the right to co-market lisinopril, and Merck received the exclusive rights to an earlier stage aldose reductase inhibitor drug candidate, a potential diabetes treatment. Zeneca's marketing and brand name, "Zestril", turned out to be stronger than Merck's effort. The drug became a blockbuster for AstraZeneca (formed in 1998), with annual sales in 1999 of $1.2B. The US patents expired in 2002. Since then, lisinopril has been available under many brand names worldwide; it is also available in combination drugs with diuretic hydrochlorothiazide (as lisinopril/hydrochlorothiazide), and with calcium channel blocker amlodipine (as lisinopril/amlodipine).
=== In Vietnam === The clinical trials of the vaccine in Vietnam are completely sponsored and funded by Vinbiocare, a Vingroup subsidiary. On 2 August, Vinbiocare received regulatory approval to start a clinical trial of its COVID-19 vaccine candidate in Vietnam. The company will coordinate with the Ministry of Health to carry out Phase I-III clinical trials of VBC-COV19-154 vaccine on 21,000 adults in three phases in August 2021. The clinical trial Phase 1 will recruit 100 volunteers to evaluate the safety, tolerability, and initial assessment of immunogenicity of the vaccine. The clinical trial Phase 2 enrolled 300 volunteers at designated medical facilities in multiple provinces, while the third phase of human trials is expected to involve 20,600 volunteers, including phase 3a (600 volunteers) and 3b (20,000 volunteers). Those receiving placebo will receive active vaccine after 6 months, while all participants will be followed up for 1 year. In December 2021, the company plans to complete and submit procedures to the Ministry of Health, applying for an emergency authorization in Vietnam.
Sources: en.wikipedia.org
In 2013, Essendon was investigated by the AFL and the Australian Sports Anti-Doping Authority (ASADA) over its 2012 player supplements program, specifically regarding the alleged use of the banned peptide Thymosin beta-4. On 27 August 2013, the AFL found the club guilty of bringing the game into disrepute for establishing a program that was "experimental, inappropriate and inadequately vetted". The club was fined A$2 million, stripped of early draft picks, and disqualified from the 2013 finals series. Senior coach James Hird was suspended for twelve months, and several executives, including chairman David Evans and CEO Ian Robson, resigned. Despite the AFL Anti-Doping Tribunal initially clearing the players in March 2015, the World Anti-Doping Agency (WADA) appealed the decision. On 12 January 2016, the Court of Arbitration for Sport overruled the AFL tribunal, finding 34 past and present players guilty of taking the banned substance. The players were suspended for the entire 2016 season. Forced to field a team composed heavily of VFL top-up players, Essendon claimed the wooden spoon in 2016 for the first time since 1933. Following the conclusion of the saga, Essendon made intermittent finals appearances, qualifying in 2017, 2019, and 2021 under coaches John Worsfold and Ben Rutten, but suffered elimination final defeats each time. The club has struggled to achieve significant post-season success, enduring a drought of finals victories that stretches back to 2004.
The ONDCP stated in April 2011 that there had been a 46% drop in cocaine use among young adults over the previous five years, and a 65% drop in the rate of people testing positive for cocaine in the workplace since 2006. At the same time, a 2007 study found that up to 35% of college undergraduates used stimulants not prescribed to them. A 2013 study found that prices of heroin, cocaine and cannabis had decreased from 1990 to 2007, while the purity of these drugs had increased. The National Survey on Drug Use and Health for 2019 found that 1.7% of US adults over 25 had used cocaine in the previous 12 months, compared to 1.8% in 2002, and cannabis use went from 7% in 2002 to 15.2%. The DEA's 2021 National Drug Threat Assessment stated that "a steady supply of cocaine was available throughout domestic markets" in 2019 and 2020. According to the Centers for Disease Control (CDC), drug abuse fatalities in 2021 reached an all-time high of 108,000 deaths, a 15% increase from 2020 (93,000) which, at the time, was the highest number of deaths and a 30% increase from 2019. During alcohol prohibition, from 1920 to 1933, alcohol use initially fell but began to increase as early as 1922. It has been extrapolated that even if prohibition had not been repealed in 1933, alcohol consumption would have surpassed pre-prohibition levels. One argument against the war on drugs is that it uses similar measures as Prohibition and is no more effective.
Piperidine is an organic compound with the molecular formula (CH2)5NH. This heterocyclic amine consists of a six-membered ring containing five methylene bridges (–CH2–) and one amine bridge (–NH–). It is a colorless liquid with an odor described as objectionable, human sperm-like, typical of amines. The name comes from the genus name Piper, which is the Latin word for pepper. Although piperidine is a common organic compound, it is best known as a representative structure element within many pharmaceuticals and alkaloids, such as naturally-occurring solenopsins.
Although one-letter symbols are included in the table, IUPAC–IUBMB recommend that "Use of the one-letter symbols should be restricted to the comparison of long sequences". The one-letter notation was chosen by IUPAC-IUB based on the following rules:
Sources: en.wikipedia.org
MacKinnon, Charlotte M.; Carter, Philip E.; Smyth, S. Jane; Dunbar, Bryan; Fothergill, John E. (1987). "Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence". European Journal of Biochemistry. 169 (3): 547–553. doi:10.1111/j.1432-1033.1987.tb13644.x. PMID 3500856. Snoke, JE; Yanari, S; Bloch, K (1953). "Synthesis of glutathione from gamma-glutamylcysteine". The Journal of Biological Chemistry. 201 (2): 573–586. doi:10.1016/S0021-9258(18)66212-X. PMID 13061393. Mandeles, S; Block, K (1955). "Enzymatic synthesis of gamma-glutamylcysteine". The Journal of Biological Chemistry. 214 (2): 639–646. doi:10.1016/S0021-9258(18)70912-5. PMID 14381401.
==== Tax deduction for qualified tip income ==== The law creates new tax deductions for tips of up to $25,000 per year received by workers earning less than $150,000, with the tax deduction set to expire in 2028. In order to be eligible, a tip must be paid voluntarily by the payor, and the payor must determine the amount of the tip. The payor must not be subject to a penalty if they do not pay a tip, and the tips must not be subject to any negotiation. The tip must be given to workers working one of 68 different job types. Tips received while performing a service that is a felony or misdemeanor are not eligible. Tips received for prostitution or pornography are not eligible. Tips received as part of a tip pool are generally eligible. Tips received directly by a supervisor or manager are eligible only if they are for services they provided in a qualified occupation and not as part of a tip pool. If the customer is charged a service charge or an automatic tip amount that is not voluntary on the part of the customer, then the service charge or tip is not eligible. This includes if the company requires a customer to pay a service charge or a particular tip amount on parties greater than a certain size. Voluntary tips above such a minimum or mandatory charge are eligible. Recommended tips are eligible if they are optional on the part of the payer. If the customer is required to select a tip amount but does not have the option to choose to not tip at all, the minimum possible tip amount is not eligible but any tips exceeding that minimum are eligible.
The currency of Singapore is the Singapore dollar (SGD or S$), issued by the Monetary Authority of Singapore (MAS). It has been interchangeable with the Brunei dollar at par value since 1967. MAS manages its monetary policy by allowing the Singapore dollar exchange rate to rise or fall within an undisclosed trading band. This is different from most central banks, which use interest rates to manage policy. Singapore has the world's eleventh largest foreign reserves, and one of the highest net international investment position per capita. Singapore has been identified as a tax haven for the wealthy due to its low tax rates on personal income and tax exemptions on foreign-based income and capital gains. Individuals such as Australian millionaire retailer Brett Blundy and multi-billionaire Facebook co-founder Eduardo Saverin are two examples of wealthy individuals who have settled in Singapore. In 2009, Singapore was removed from the Organisation for Economic Co-operation and Development (OECD) "liste grise" of tax havens, and ranked fourth on the Tax Justice Network's 2015 Financial Secrecy Index of the world's off-shore financial service providers, banking one-eighth of the world's offshore capital, while "providing numerous tax avoidance and evasion opportunities". In August 2016, The Straits Times reported that Indonesia had decided to create tax havens on two islands near Singapore to bring Indonesian capital back into the tax base.
At the cellular level, the main functional component of bone marrow includes the progenitor cells which are destined to mature into blood and lymphoid cells. Human marrow produces approximately 500 billion blood cells per day. Marrow contains hematopoietic stem cells which give rise to the three classes of blood cells that are found in circulation: white blood cells (leukocytes), red blood cells (erythrocytes), and platelets (thrombocytes).
Reactions with larger nitriles, however, are only marginally accelerated, implying that catalysis takes place chiefly within the material's channels rather than on its exterior. A noteworthy finding is the lack of catalysis by the free strut in homogeneous solution, evidently due to intermolecular H-bonding between bptda molecules. Thus, the MOF architecture elicits catalytic activity not otherwise encountered. In an interesting alternative approach, Férey and coworkers were able to modify the interior of MIL-101 via Cr(III) coordination of one of the two available nitrogen atoms of each of several ethylenediamine molecules. The free non-coordinated ends of the ethylenediamines were then used as Brønsted basic catalysts, again for Knoevenagel condensation of benzaldehyde with nitriles. A third approach has been described by Kim Kimoon and coworkers. Using a pyridine-functionalized derivative of tartaric acid and a Zn(II) source they were able to synthesize a 2D MOF termed POST-1. POST-1 possesses 1D channels whose cross sections are defined by six trinuclear zinc clusters and six struts. While three of the six pyridines are coordinated by zinc ions, the remaining three are protonated and directed toward the channel interior. When neutralized, the noncoordinated pyridyl groups are found to catalyze transesterification reactions, presumably by facilitating deprotonation of the reactant alcohol. The absence of significant catalysis when large alcohols are employed strongly suggests that the catalysis occurs within the channels of the MOF.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.